{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:19:16Z","timestamp":1790104756963,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS032677"],"award-info":[{"award-number":["R01 NS032677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013149","name":"Meningioma Mommas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113843","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T05:14:45Z","timestamp":1665206085000},"page":"113843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma"],"prefix":"10.1016","volume":"155","author":[{"given":"Yoichiro","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gurtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ego","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gorham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Martuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-241X","authenticated-orcid":false,"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113843_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2022.113843_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2022.113843_bib3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113843_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2011","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib5","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.113843_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2022.113843_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.113843_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2022.113843_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2022.113843_bib14","doi-asserted-by":"crossref","first-page":"E461","DOI":"10.1093\/neuros\/nyy610","article-title":"Malignant meningioma: an international multicentre retrospective study","volume":"85","author":"Champeaux","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.biopha.2022.113843_bib15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3171\/2017.2.JNS162282","article-title":"Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012","volume":"128","author":"Orton","year":"2018","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.biopha.2022.113843_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2022.113843_bib17","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/ijc.30929","article-title":"Blockade of transforming growth factor-beta signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models","volume":"141","author":"Esaki","year":"2017","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2022.113843_bib18","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/ijc.30811","article-title":"Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus","volume":"141","author":"Jahan","year":"2017","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2022.113843_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jnci\/djr509","article-title":"Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells","volume":"104","author":"Kanai","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2022.113843_bib20","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/neuonc\/now031","article-title":"A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus","volume":"18","author":"Nigim","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2022.113843_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw229","article-title":"Rad51 degradation: role in oncolytic virus-poly(ADP-Ribose) polymerase inhibitor combination therapy in glioblastoma","volume":"109","author":"Ning","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2022.113843_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5966\/sctm.2011-0035","article-title":"Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells","volume":"1","author":"Sgubin","year":"2012","journal-title":"Stem Cells Transl. Med"},{"key":"10.1016\/j.biopha.2022.113843_bib23","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113843_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial","author":"Todo","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.113843_bib25","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1158\/1078-0432.CCR-17-1717","article-title":"Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models","volume":"24","author":"Saha","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113843_bib26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.biopha.2022.113843_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113843_bib28","first-page":"13","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","author":"Jenke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2022.113843_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v8010009","article-title":"Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade","volume":"8","author":"Marchini","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2022.113843_bib30","first-page":"183","article-title":"Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy","volume":"4","author":"Nakashima","year":"2015","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.biopha.2022.113843_bib31","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113843_bib32","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113843_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11523-019-00654-4","article-title":"A monoclonal antibody against beta1 integrin inhibits proliferation and increases survival in an orthotopic model of high-grade meningioma","volume":"14","author":"Nigim","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.biopha.2022.113843_bib34","doi-asserted-by":"crossref","first-page":"11997","DOI":"10.1073\/pnas.1816399116","article-title":"Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6","volume":"116","author":"Lu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113843_bib35","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguyen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113843_bib36","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113843_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2022.113843_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cgt.2008.81","article-title":"The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells","volume":"16","author":"Katsura","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2022.113843_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/mt.2008.58","article-title":"Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects","volume":"16","author":"Liu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2022.113843_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092919","article-title":"Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells","volume":"9","author":"Cody","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113843_bib41","first-page":"10","article-title":"High-throughput mechanistic screening of epigenetic compounds for the potential treatment of meningiomas","author":"Tatman","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2022.113843_bib42","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1172\/JCI80713","article-title":"Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma","volume":"125","author":"Nakashima","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2022.113843_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127058","article-title":"The HDAC Inhibitors scriptaid and LBH589 combined with the oncolytic virus delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells","volume":"10","author":"Berghauser Pont","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113843_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/v13091836","article-title":"A review of the multipronged attack of herpes simplex virus 1 on the host transcriptional machinery","volume":"13","author":"Hennig","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2022.113843_bib45","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1128\/JVI.75.9.4376-4385.2001","article-title":"Herpes simplex virus IE63 (ICP27) protein interacts with spliceosome-associated protein 145 and inhibits splicing prior to the first catalytic step","volume":"75","author":"Bryant","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2022.113843_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2010.02.023","article-title":"SR proteins SRp20 and 9G8 contribute to efficient export of herpes simplex virus 1 mRNAs","volume":"401","author":"Escudero-Paunetto","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2022.113843_bib47","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1128\/jvi.69.10.6063-6076.1995","article-title":"The C-terminal repressor region of herpes simplex virus type 1 ICP27 is required for the redistribution of small nuclear ribonucleoprotein particles and splicing factor SC35; however, these alterations are not sufficient to inhibit host cell splicing","volume":"69","author":"Sandri-Goldin","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2022.113843_bib48","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.05545-11","article-title":"The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5\/T-BET signaling and generation of gamma interferon","volume":"86","author":"Alvarez-Breckenridge","year":"2012","journal-title":"J. Virol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201232X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222201232X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:20:37Z","timestamp":1781781637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222201232X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"alternative-id":["S075333222201232X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113843","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113843"}}